Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland.

Karesvuo, Petteri; Hakkala, Laura; Kaarniranta, Kai; Uusitalo, Hannu; Ojamo, Matti; Tuuminen, Raimo

Karesvuo, Petteri; Hakkala, Laura; Kaarniranta, Kai; Uusitalo, Hannu; Ojamo, Matti; Tuuminen, Raimo.

Afiliação

Karesvuo P; Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.
Hakkala L; Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland.
Kaarniranta K; Department of Ophthalmology, Turunmaa Regional Hospital, Turku, Finland.
Uusitalo H; Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Ojamo M; Department of Ophthalmology, University Hospital, Kuopio, Finland.
Tuuminen R; SILK, Department of Ophthalmology, Tampere University and Tays Eye Center, Tampere, Finland.

Acta Ophthalmol ; 98(5): 472-476, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32096347

Palavras-chave

aflibercept; anti-vascular endothelial growth factor; treat-and-extend regimen; visual impairment; wet age-related macular degeneration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Acta Ophthalmol Assunto da revista: OFTALMOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Finlândia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google